LB Pharmaceuticals (NASDAQ:LBRX) CEO Heather Turner told investors the company is positioned for a series of “clinically meaningful value creating catalysts” following its most recent financing, with multiple late-stage readouts planned for its lead candidate LB-102 across several psychiatric indications. In a discussion moderated as a conversational company update, Turner emphasized that LB-102 is intended […]